World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
105
Citations
62139
World Ranking
574
National Ranking
342

Medicine

D-Index
106
Citations
62294
World Ranking
6377
National Ranking
3398

Richard A. Morgan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard A. Morgan sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 283 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Richard A. Morgan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard A. Morgan sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 105 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 1954 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Richard A. Morgan is affiliated with the University of California, Los Angeles in the United States. Their research spans multiple areas of medicine and molecular biology with significant contributions in oncology, immunology, surgery, and emergency medicine.

The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields cover Oncology, Molecular Biology, Immunology, Surgery, and Emergency Medicine. The primary topics Richard Morgan has worked on range across CAR-T cell therapy research, CRISPR and genetic engineering, immune cell function and interaction, virus-based gene therapy research, mosquito-borne diseases and control, bariatric surgery and outcomes, and esophageal and gastrointestinal pathology.

Frequent publication venues for their work include Blood, Nature Communications, Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), and Surgical Endoscopy.

Richard Morgan has collaborated multiple times with several co-authors, notably Kevin Wasko, Steven Sexton, Christopher M. Borges, Jared Nasser, and Lincy Prem Antony.

Selected recent papers demonstrate a diverse range of topics and publication venues:

  • AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines (2021, Nature Communications)
  • Closure versus non-closure of mesenteric defects in laparoscopic Roux-en-Y gastric bypass: a systematic review and meta-analysis (2020, Surgical Endoscopy)
  • The incidence of right-sided colon cancer in patients aged over 40 years with acute appendicitis: A systematic review and meta-analysis (2020, International Journal of Surgery)
  • Author Correction: AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines (2021, Nature Communications)
  • Neuromodulation Techniques in Chronic Refractory Coccydynia: A Narrative Review (2024, Pain and Therapy)

Richard A. Morgan has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 1954.

Best Publications

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Genomic analyses identify molecular subtypes of pancreatic cancer

    Bailey P;Chang Dk;Nones K;Nones K;Johns Al

  • Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

    Richard A Morgan;James C Yang;Mio Kitano;Mark E Dudley

  • Whole genomes redefine the mutational landscape of pancreatic cancer.

    Nicola Waddell;Marina Pajic;Ann Marie Patch;David K. Chang

  • Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

    Andrew V. Biankin;Andrew V. Biankin;Andrew V. Biankin;Nicola Waddell;Karin S. Kassahn;Marie Claude Gingras

  • T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years

    R. Michael Blaese;Kenneth W. Culver;A. Dusty Miller;Charles S. Carter

  • Adoptive cell transfer: a clinical path to effective cancer immunotherapy

    Steven A. Rosenberg;Nicholas P. Restifo;James C. Yang;Richard A. Morgan

  • Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.

    Natasha J. Caplen;Susan Parrish;Farhad Imani;Andrew Fire

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

    James N. Kochenderfer;Mark E. Dudley;Steven A. Feldman;Wyndham H. Wilson

  • Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction

    Steven A. Rosenberg;Paul Aebersold;Kenneth Cornetta;Attan Kasid

  • Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

    Laura A. Johnson;Richard A. Morgan;Mark E. Dudley;Lydie Cassard

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

    James N. Kochenderfer;Wyndham H. Wilson;John E. Janik;Mark E. Dudley

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

    B Ensoli;L Buonaguro;G Barillari;V Fiorelli

  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  • Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Waleed Haso;Daniel W. Lee;Nirali N. Shah;Maryalice Stetler-Stevenson

  • Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability

    Cyrille J. Cohen;Yangbing Zhao;Zhili Zheng;Steven A. Rosenberg

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Zhiya Yu
Zhiya Yu National Institutes of Health
W. French Anderson
W. French Anderson University of Southern California
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Bruce A. Bunnell
Bruce A. Bunnell University of North Texas Health Science Center
James N. Kochenderfer
James N. Kochenderfer National Institutes of Health
Luca Gattinoni
Luca Gattinoni University of Regensburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare careers often require strong clinical knowledge and nursing skills. Exploring various nursing programs can open doors to roles that work closely with immunological research and patient care.

Many students look for flexible options such as accelerated rn to np programs, which allow registered nurses to quickly advance to nurse practitioner roles, gaining advanced expertise that can complement immunology studies.

If you are new to nursing, online rn programs for non nurses in florida provide accessible pathways to becoming a registered nurse, setting a foundation for future specialization in immunology-focused careers.

For quicker entry into nursing, consider 12-month accelerated nursing programs, which offer intensive training for students seeking to fast-track their careers and apply their skills in immunology-related healthcare settings.

Additionally, which lpn programs are easiest to get into is a valuable resource for those exploring practical nursing as a starting point, enabling entry-level experience that can later support advanced immunology education.

Best Scientists Citing Richard A. Morgan

Trending Scientists

Recently Published Articles